Kaplan Fox Alerts Beta Bionics, Inc. (BBNX) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is November 3, 2026

    125 Aufrufe 125 0 Kommentare 0 Kommentare
    Kaplan Fox Alerts Beta Bionics, Inc. (BBNX) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is November 3, 2026

    New York, New York--(Newsfile Corp. - October 7, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period").

    CLICK HERE TO JOIN THE CASE

    If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

    DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

    Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas insulin pump ("iLet"), an automated insulin delivery system. The complaint alleges that throughout the Class Period, Beta Bionics received thousands of complaints from iLet customers, including numerous reports of serious, life-threatening hypoglycemia caused by device malfunctions that required hospitalization to treat. The root cause of these malfunctions was allegedly iLet's extremely aggressive dosing algorithm.

    The truth was allegedly revealed through a series of disclosures starting on January 8, 2026 when Beta Bionics surprised investors with a miss on the key metric of new iLet patient starts, which was followed by a 37% one-day stock price decline. Finally, on February 24, 2026, the full truth was allegedly revealed when the U.S. Food and Drug Administration (the "FDA") publicly released its warning letter detailing a litany of violations and Defendants' failure to correct them, and contradicting months of Defendants' public statements that all back-filed complaints were for entirely benign issues. According to the complaint, the warning letter made clear that Defendants' prior interpretation of FDA reporting requirements had not been reasonable, and had excluded numerous serious patient incidents that clearly should have been reported.

    Seite 1 von 2 






    Verfasst von newsfile
    Kaplan Fox Alerts Beta Bionics, Inc. (BBNX) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is November 3, 2026 New York, New York--(Newsfile Corp. - October 7, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that …

    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Profitieren Sie von unserem Alleinstellungsmerkmal als den zentralen verlagsunabhängigen Wissens-Hub für einen aktuellen und fundierten Zugang in die Börsen- und Wirtschaftswelt, um strategische Entscheidungen zu treffen.
    • ✅ Größte Finanz-Community Deutschlands
    • ✅ über 550.000 registrierte Nutzer
    • ✅ rund 2.000 Beiträge pro Tag
    • ✅ verlagsunabhängige Partner ARIVA, FinanzNachrichten und BörsenNews
    • ✅ Jederzeit einfach handeln beim SMARTBROKER+
    • ✅ mehr als 25 Jahre Marktpräsenz
    Aktien von A - Z: # A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    wallstreetONLINE bei X wallstreetONLINE bei Instagram wallstreetONLINE bei Facebook wallstreetONLINE bei Youtube wallstreetONLINE bei LinkedIn
    Unsere Apps: Apple App Store Icon Google Play Store Icon
    Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

    Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
    Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
    Copyright © 1998-2026 Smartbroker Holding AG - Alle Rechte vorbehalten.
    Mit Unterstützung von: Ariva Smartbroker+
    Daten & Kurse von: TTMzero